Minamimoto Ryogo, Hotta Masatoshi, Okafuji Takashi, Tsutui Soichiro, Tsukuda Masaaki, Nakayama Hidetsugu, Shida Yoshitaka, Tajima Tsuyoshi
Division of Nuclear Medicine, Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
Glob Health Med. 2022 Apr 30;4(2):108-115. doi: 10.35772/ghm.2022.01016.
The aim of this study is to clarify changes in the circumstances of cancer diagnoses during the COVID-19 pandemic in Tokyo, Japan, estimated from [F]-2-fluoro-2-deoxy-D-glucose (FDG) -positron emission tomography/ computed tomography (PET/CT) for cancer patients. Cancer diagnosis in pandemic status (PANS) was evaluated by retrospective review of the findings of FDG-PET/CT examinations performed between 11 March 2020 and 28 December 2021 for initial staging and restaging for malignancy. Evaluation of cancer diagnosis in pre-pandemic status (pPANS) was conducted similarly in FDG-PET/CT examinations performed between 4 January 2018 and 10 March 2020. Of these, patients with malignant lymphoma (ML), lung cancer, esophageal cancer, and colorectal cancer who had a pathologically proven diagnosis or clinical diagnosis following therapy of the disease were selected for analysis. Initial cancer staging was determined by the diagnostic report of FDG-PET/CT. Change in cancer stage and in the number of FDG-PET/CT examinations performed was evaluated between pPANS and PANS, and according to term of the pandemic and vaccination status. The COVID-19 epidemic influenced the number of cancer patients who underwent FDG-PET/CT. There was a marked decrease in the number of cancer patients receiving FDG-PET/CT in Terms 1-3 (March 2020 to February 2021), but it recovered in Terms 4-6 (March 2021 to December 2021). There was no significant difference between PANS and pPANS in terms of the initial stage of cancer, but Stage IV ML and Stage II esophageal cancer were more frequent in PANS. Initial staging of ML, lung cancer, and esophageal cancer revealed more advanced cancer stages in Terms 4-6 compared with Terms 1-3. The number of patients receiving FDG-PET/CT in Tokyo was influenced by the COVID-19 epidemic. Staging based on FDG-PET/CT shifted to more advanced cancer stage during the pandemic compared with pre-pandemic.
本研究旨在通过对癌症患者进行的[F]-2-氟-2-脱氧-D-葡萄糖（FDG）-正电子发射断层扫描/计算机断层扫描（PET/CT），阐明日本东京在2019冠状病毒病大流行期间癌症诊断情况的变化。通过回顾性分析2020年3月11日至2021年12月28日期间进行的FDG-PET/CT检查结果，对处于大流行状态（PANS）的癌症诊断进行评估，以用于恶性肿瘤的初始分期和再分期。对处于大流行前状态（pPANS）的癌症诊断评估，同样是对2018年1月4日至2020年3月10日期间进行的FDG-PET/CT检查进行。其中，选择经病理证实诊断或疾病治疗后临床诊断为恶性淋巴瘤（ML）、肺癌、食管癌和结直肠癌的患者进行分析。癌症的初始分期由FDG-PET/CT的诊断报告确定。评估pPANS和PANS之间癌症分期以及所进行的FDG-PET/CT检查数量的变化，并根据大流行时期和疫苗接种状况进行评估。2019冠状病毒病疫情影响了接受FDG-PET/CT检查的癌症患者数量。在第1-3期（2020年3月至2021年2月）接受FDG-PET/CT检查的癌症患者数量显著减少，但在第4-6期（2021年3月至2021年12月）有所恢复。PANS和pPANS在癌症初始分期方面无显著差异，但IV期ML和II期食管癌在PANS中更为常见。与第1-3期相比，ML、肺癌和食管癌的初始分期在第4-6期显示出更晚期的癌症阶段。东京接受FDG-PET/CT检查的患者数量受到2019冠状病毒病疫情的影响。与大流行前相比，在大流行期间基于FDG-PET/CT的分期转变为更晚期的癌症阶段。
